A novel, non-opioid, selective orexin-1 receptor antagonist for the treatment of substance use disorders.

Neurosci Appl · 2024 · PMC12244226 · PMID 40656120

Europe PMC DOI

hedged sentences

0.0500

closest p · 1.0× alpha

0.0800

boldest claim

The sentences

of borderline significanceP = 0.05actually significant

On analysis of nicotine infusions, although no main effect of treatment was recorded, a treatment by day interaction of borderline significance was noted (F16,152 = 1.7, P = 0.05) reflecting a treatment effect on infusions related to the test day.

also in 2,624 other papers

of marginal significanceP = 0.08so close (0.05 < p ≤ 0.1)

Consequently, within day analysis on infusions was investigated and Day 4 was of marginal significance (F4,38 = 2.2, P = 0.08) and Day 5 significant (F4,38 = 2.8, P = 0.04).

also in 464 other papers

did not reach statistical significanceno p-value reported

There was also a reduction of responding (approximately 40%) with regard to the arithmetic means in reinstatement Session 2, although this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.